Citations

Clear

350 citation(s) found for "Stevens, V".

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
Belada, David , Kopečková, Kateřina , Bergua, Juan , Stevens, Don A., André, Marc , Pichler, Petra , Staber, Philipp B. , Trněný, Marek , Duell, Johannes , Waldron-Lynch, Maeve, Wagner, Steve, Mukhopadhyay, Amitava , Dirnberger‐Hertweck, Maren, Burke, John M. , Nowakowski, Grzegorz S. , Bergua, Juan Miguel , Staber, Philipp B , Trnĕný, Marek , Mukhopadhyay, Amitava , Burke, John M , Persona, Ernesto Pérez

Mayo Clinic

Blood | June 27, 2023 | Volume: 142 | Issue: 16 | Pages: 1348-1358

10.1182/blood.2023020637 | PMID 37369099 Get It

Abstract Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles. Primary end point was safety; secondary end points included end-of-treatment (EoT) overall response rate (ORR) and complete response (CR) rate. All patients had ≥1 treatment-emergent adverse event, mostly grade 1 or 2. Grade ≥3 neutropenia and thrombocytopenia occurred, respectively, in 57.6% and 12.1% (arm T) and 84.8% and 36.4% (arm T/L) of patients. Nonhematologic toxicities occurred at similar rates among arms. R-CHOP mean relative dose intensity was ≥89% in both arms. EoT ORR was 75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and of CR rates were 72.7% and 74.5% (arm T) and 78.7% and 86.5% (arm T/L); 24-month progression-free and overall survival rates were 72.7% and 90.3% (arm T) and 76.8% and 93.8% (arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab + lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092). This study is registered at www.clinicaltrials.gov as #NCT04134936.
Fentanyl-Associated Overdose Deaths Outside the Hospital
Jeffery, Molly M. , Stevens, Maria , D’Onofrio, Gail , Melnick, Edward R. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

New England Journal of Medicine | June 21, 2023 | Volume: 389 | Issue: 1 | Pages: 87-88

10.1056/nejmc2304991 | PMID 37342960 Get It

Failure of mecA/mecC PCR Testing to Accurately Predict Oxacillin Resistance in a Patient with Staphylococcus aureus Infective Endocarditis
Hess, Kyle A., Kooda, Kirstin , Shirley, Joshua D. , Schuetz, Audrey N. , Saleh, Omar Abu , Stevens, Ryan W. , Abu Saleh, Omar , Schuetz, Audrey N , Stevens, Ryan W

Mayo Clinic

Antimicrobial Agents and Chemotherapy | June 21, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00437-23 | PMID 37341623 Get It

Genotypic testing for mecA / mecC is heavily relied upon for rapid optimization of antimicrobial therapy in infections due to Staphylococcus aureus . Little is known regarding optimal reporting and/or therapy for patients demonstrating lack of genotypic evidence of mecA or mecC but phenotypic oxacillin resistance.
Tibial Spine Fractures in the Child and Adolescent Athlete: A Systematic Review and Meta-analysis
Orellana, Kevin J., Houlihan, Nathan, Carter, Michael V. , Baldwin, Keith D. , Stevens, Alexandra C. , Ellis, Henry B. , Kushare, Indranil , Johnson, B. Lamar , Kerrigan, Alicia , Kirby, Julia, McKay, Scott , Milbrandt, Todd A. , Mistovich, R. Justin , Schmale, Gregory A. , Traver, Jessica L. , Ganley, Theodore J. , Carter, Michael V., Baghdadi, Soroush , Cruz, Aristides I. , Green, Daniel W , MacDonald, James Patrick , Parikh, Shital N. , Patel, Neeraj M. , Yen, Yi‐Meng

Mayo Clinic

The American Journal of Sports Medicine | June 16, 2023 | Volume: 52 | Issue: 5 | Pages: 1357-1366

10.1177/03635465231175674 | PMID 37326248 Get It

Background: Tibial spine fractures (TSFs) are uncommon injuries that may result in substantial morbidity in children. A variety of open and arthroscopic techniques are used to treat these fractures, but no single standardized operative method has been identified. Purpose: To systematically review the literature on pediatric TSFs to determine the current treatment approaches, outcomes, and complications. Study Design: Meta-analysis; Level of evidence, 4. Methods: A systematic review of the literature was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines using PubMed, Embase, and Cochrane databases. Studies evaluating treatment and outcomes of patients <18 years old were included. Patient demographic characteristics, fracture characteristics, treatments, and outcomes were abstracted. Descriptive statistics were used to summarize categorical and quantitative variables, and a meta-analytic technique was used to compare observational studies with sufficient data. Results: A total of 47 studies were included, totaling 1922 TSFs in patients (66.4% male) with a mean age of 12 years (range, 3-18 years). The operative approach was open reduction and internal fixation in 291 cases and arthroscopic reduction and internal fixation in 1236 cases; screw fixation was used in 411 cases and suture fixation, in 586 cases. A total of 13 nonunions were reported, occurring most frequently in Meyers and McKeever type III fractures (n = 6) and in fractures that were treated nonoperatively (n = 10). Arthrofibrosis rates were reported in 33 studies (n = 1700), and arthrofibrosis was present in 190 patients (11.2%). Range of motion loss occurred significantly more frequently in patients with type III and IV fractures ( P < .001), and secondary anterior cruciate ligament (ACL) injury occurred most frequently in patients with type I and II fractures ( P = .008). No statistically significant differences were found with regard to rates of nonunion, arthrofibrosis, range of motion loss, laxity, or secondary ACL injury between fixation methods (screw vs suture). Conclusion: Despite variation in TSF treatment, good overall outcomes have been reported with low complication rates in both open and arthroscopic treatment and with both screw and suture fixation. Arthrofibrosis remains a concern after surgical treatment for TSF, but no significant difference in incidence was found between the analysis groups. Larger studies are necessary to compare outcomes and form a consensus on how to treat and manage patients with TSFs.
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)
Lekakis, Lazaros J. , Eradat, Herbert, Tees, Michael, Vos, Sven de , Nath, R., Stevens, Don A., Popplewell, Leslie , Goyal, Lovely, Navale, Lynn, Kaufman, G., Kai, Kazuharu, Balakumaran, Arun, Neelapu, Sattva S. , Locke, Frederick L. , Muñoz, Javier , Malik, S., Hamadani, Mehdi , Oluwole, Olalekan O. , Perales, Miguel‐Angel , Miklos, David B. , Fisher, Paul Graham

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 85-86

10.1002/hon.3163_48 Get It

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Lekakis, Lazaros J. , Eradat, Herbert, Tees, Michael, Vos, Sven de , Nath, Rajneesh , Stevens, Don A., Malik, Shahbaz A. , Popplewell, Leslie , Goyal, Lovely, Kaufman, Gregory, Kai, Kazuharu, Balakumaran, Arun, Neelapu, Sattva S. , Locke, Frederick L. , Muñoz, Javier , Hamadani, Mehdi , Oluwole, Olalekan O. , Perales, Miguel‐Angel , Miklos, David B. , Fisher, Paul Graham

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 2517-2517

10.1200/jco.2023.41.16_suppl.2517 Get It

2517 Background: Approximately 50% to 60% of pts with r/r LBCL will either not achieve a complete response (CR) or will relapse with current treatments and require additional therapy. Autologous anti-CD19 chimeric antigen receptor T (CAR T) therapies have revolutionized the care of patients whose disease progresses following standard therapies, but patient-specific manufacturing processes and long wait times to treatment present challenges for their broad clinical use. Allogeneic (healthy-donor-derived), off-the-shelf, anti-CD19 (CAR T) treatment promises broader and more rapid access to one-dose treatment with curative intent. Initial phase 1 data for the anti-CD19 AlloCAR T cell product ALLO-501 (NCT03939026) and successor, ALLO-501A (NCT04416984), demonstrated a manageable safety profile with no dose-limiting toxicities (DLTs), and efficacy comparable to autologous CAR T therapy in pts with r/r LBCL who were autologous CAR T-naïve. This update provides additional follow up and a focus on participants who received the conditioning regimen and cells made with an optimized manufacturing process currently under study in the first potentially pivotal trial for an allogeneic CAR T product. Methods: In these two multicenter, single-arm, open-label, phase 1 trials, a cohort of autologous CAR T-naïve pts with r/r LBCL underwent 3-day lymphodepletion (LD) with FCA90, fludarabine (F, 30 mg/m2/day), cyclophosphamide (C, 300 mg/m2/day), and ALLO-647 (A [anti-CD 52 mAb] 30 mg/day; total dose: 90 mg) followed by a single dose of ALLO-501 or ALLO-501A produced by the Alloy manufacturing process. Results: As of Jan 26, 2023, 12 pts received the FCA90 LD regimen and CAR T therapy with 100% receiving product per specifications with a median time from enrollment to LD of 3 days. Median follow-up time (actual) was 7.1 months (range: 1.4, 36.0). No DLTs, severe (Gr3+) cytokine-release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD) events occurred. An overall response rate and a CR rate of 66.7% and 58.3%, respectively, were observed. Median DOR was 23.1 months. Among 8 pts with the opportunity to be followed for 6 months, 5 (62.5%) had achieved CR and 4 (50.0%) sustained CR through 6 months. Analyses of vector copy number pharmacokinetics at Days 28 and 56 documented substantial and sustained expansion of CAR T cells. Conclusions: A one-time dose of allogeneic CAR T therapy following LD with FCA90 provided durable responses with a manageable safety profile in patients with r/r/ LBCL comparable to those treated with autologous CAR T cells. This treatment enables rapid access to off-the-shelf treatment with a median time from trial enrollment to treatment of 3 days. These findings support broader evaluation of ALLO-501A in the ongoing, first potentially pivotal phase 2 trial (ALPHA2) of off-the-shelf allogeneic CAR T cells. Clinical trial information: NCT03939026 .
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis
Waters, Margo , Dobry, Allison S. , Le, Stephanie T. , Shinkai, Kanade , Beachkofsky, Thomas M. , Davis, Mark D.P. , Markova, Alina , Pasieka, Helena B. , Rosenbach, Misha , Seminario‐Vidal, Lucia , Trinidad, John , Altman, Emily , Arakaki, Ryan, Ardern‐Jones, Michael R. , Bridges, Alina G. , Cardones, Adela R. , Chen, Jennifer K. , Chen, Steven T. , Cheng, Kyle , Harp, Joanna, King, Brett , Lowenstein, Eve J. , Luxenberg, Erin, Mancuso, Jennifer , Mauskar, Melissa , Milam, Philip , Nelson, Caroline A. , Nguyen, Cuong V. , Nutan, Fnu, Patel, Tejesh , Rahnama‐Moghadam, Sahand , Rekhtman, Sergey , Rojek, Nathan W. , Sarihan, Mansi, Shaigany, Sheila , Sharma, Timmie R. , Shearer, Sabrina M, Shields, Bridget E. , Strowd, Lindsay C. , Tartar, Danielle , Walls, Andrew C., Ziemer, Carolyn, Kaffenberger, Benjamin H. , Nguyen, C V , Seminario-Vidal, L , Kaffenberger, B , Dominguez, Arturo Ricardo , Kroshinsky, Daniela , Micheletti, Robert , Mostaghimi, Arash , Albrecht, Joerg , Chadha, Angad , Daveluy, Steven , DeNiro, Katherine L. , Keller, Jesse Joel , Korman, Abraham Moris , Motaparthi, Kiran , Ortega‐Loayza, Alex G. , Shaigany, Sheila , Thomas, Cristina , Wanat, Karolyn A. , Walls, Andrew F. , Zaba, Lisa C. , Maverakis, Emanual Michael

Mayo Clinic

JAMA Dermatology | May 31, 2023 | Volume: 159 | Issue: 7 | Pages: 772

10.1001/jamadermatol.2023.1347 | PMID 37256599 Get It

Importance Scoring systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosis and are weighted toward comorbidities and systemic features; morphologic terminology for EN lesions is inconsistent. Objectives To establish consensus among expert dermatologists on EN terminology, morphologic progression, and most-affected sites, and to build a framework for developing a skin-directed scoring system for EN. Evidence Review A Delphi consensus using the RAND/UCLA appropriateness criteria was initiated with a core group from the Society of Dermatology Hospitalists to establish agreement on the optimal design for an EN cutaneous scoring instrument, terminology, morphologic traits, and sites of involvement. Findings In round 1, the 54 participating dermatology hospitalists reached consensus on all 49 statements (30 appropriate, 3 inappropriate, 16 uncertain). In round 2, they agreed on another 15 statements (8 appropriate, 7 uncertain). There was consistent agreement on the need for a skin-specific instrument; on the most-often affected skin sites (head and neck, chest, upper back, ocular mucosa, oral mucosa); and that blanching erythema, dusky erythema, targetoid erythema, vesicles/bullae, desquamation, and erosions comprise the morphologic traits of EN and can be consistently differentiated. Conclusions and Relevance This consensus exercise confirmed the need for an EN skin-directed scoring system, nomenclature, and differentiation of specific morphologic traits, and identified the sites most affected. It also established a baseline consensus for a standardized EN instrument with consistent terminology.
“How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill
Ausman, Sara , Moreland-Head, Lindsay , Saleh, Omar Abu , Jannetto, Paul J. , Rivera, Christina G. , Wessel, Rebecca J , Wieruszewski, Patrick M. , Frazee, Erin N. , group, For the BLOOM Study, Ausman, Sara E , Moreland-Head, Lindsay N , Abu Saleh, Omar M, Wessel, Rebecca J , Wieruszewski, Patrick M , Frazee, Erin N , Rivera, Christina G , Stevens, Ryan W. , group, For the BLOOM Study

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 29, 2023 | Volume: 6 | Issue: 8 | Pages: 964-975

10.1002/jac5.1819 | PMID 37731602 Get It

AbstractBeta‐lactam therapeutic drug monitoring (TDM) can improve precision dosing and clinical outcomes in critically ill patients, but has not been implemented widely in the United States. Mayo Clinic recently implemented a beta‐lactam TDM program. This single‐center experience forms the basis of the manuscript which outlines practical considerations involved with beta‐lactam TDM implementation, including the pharmacist's role as a leader. Our implementation effort focused on three primary domains. First, we aimed to ensure a supportive organizational infrastructure. Early leadership engagement by the pharmacist‐led core team facilitated advocacy for the clinical need, allocation of resources, and assay development. Second, core clinical workflows were developed that addressed the preferred patient population for use, desirable pharmacokinetic and pharmacodynamic targets, and the preferred sampling strategy. Clinical tools to guide pharmacists in interpreting the results (e.g., pharmacokinetics calculator) and documenting decisions were developed. Third, stakeholders were offered repeated exposure to evidence and expertise to facilitate understanding and application of the new practice. This act of ‘individual internalization’ seems to be uniquely important to beta‐lactam TDM implementation compared with the implementation of other antimicrobial TDM programs. Educational strategies and supportive materials that were developed were focused on providing substantive and varied information tailored to the stakeholders' role in the process. For pharmacists, this included both clinical and operational considerations. A continuous improvement plan to support management of the process was instituted to address necessary updates and changes that inevitably emerged. In summary, the described approach to implementation of a pharmacist‐led beta‐lactam TDM program could be used as a roadmap to aid other institutions that aim to develop such a program.
Comparison of Oral and Intravenous Definitive Antibiotic Therapy for Beta-Hemolytic Streptococcus Species Bloodstream Infections from Soft Tissue Sources: a Propensity Score-Matched Analysis
Yetmar, Zachary A. , Chesdachai, Supavit , Lahr, Brian D. , Epps, Kevin , Seville, Maria Teresa , Virk, Abinash , Challener, Douglas W. , Arensman Hannan, Kellie N, Yetmar, Zachary A , Chesdachai, Supavit , Hannan, Kellie N. Arensman , Stevens, Ryan W. , Tande, Aaron J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 16, 2023 | Volume: 67 | Issue: 6 | Pages: No page available

10.1128/aac.00120-23 | PMID 37191533 Get It

Beta-hemolytic streptococci are common causes of bloodstream infection (BSI). There is emerging data regarding oral antibiotics for BSI but limited for beta-hemolytic streptococcal BSI.
Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis
Adema, Jennifer L. , Ahiskali, Aileen , Hornback, Krutika Mediwala , Rivera, Christina G. , Mediwala Hornback, Krutika , Rivera, Christina G , Fida, Madiha , Stevens, Ryan W.

Mayo Clinic

Pathogens | May 12, 2023 | Volume: 12 | Issue: 5 | Pages: 703

10.3390/pathogens12050703 | PMID 37242373 Get It

Infective endocarditis (IE) is a rare but increasingly prevalent disease with high morbidity and mortality, requiring antimicrobials and at times surgical intervention. Through the decades of healthcare professionals’ experience with managing IE, certain dogmas and uncertainties have arisen around its pharmacotherapy. The introduction of new antimicrobials and novel combinations are exciting developments but also further complicate IE treatment choices. In this review, we provide and evaluate the relevant evidence focused around contemporary debates in IE treatment pharmacotherapy, including beta-lactam choice in MSSA IE, combination therapies (aminoglycosides, ceftaroline), the use of oral antimicrobials, the role of rifamycins, and long-acting lipoglycopeptides.